Each filer's latest filing for N5749R100 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (6) | ||||
|
Commodore Capital LP
13G/A
|
4.7% |
8/14/2025
Event 6/30/2025
|
||
| Commodore Capital LP | 4.7% | |||
| Commodore Capital Master LP | 4.7% | |||
|
FMR LLC
13G/A
|
3.7% |
11/5/2025
Event 9/30/2025
|
||
| FMR LLC | 3.7% | |||
| Abigail P. Johnson | 3.7% | |||
|
RTW Investments, LP
13G/A
|
2.7% |
11/14/2025
Event 9/30/2025
|
||
| RTW Investments, LP | 2.7% | |||
| Roderick Wong | 2.7% | |||
|
Wellington Management Group LLP
13G/A
|
0.6% |
11/12/2025
Event 9/30/2025
|
||
| Wellington Management Group LLP | 0.6% | |||
| Wellington Group Holdings LLP | 0.6% | |||
| Wellington Investment Advisors Holdings LLP | 0.6% | |||
|
Genmab A/S
13D/A
|
0% |
12/30/2025
Event 12/30/2025
|
||
| Genmab A/S | 0% | |||
| Genmab Holding II B.V. | 0% | |||
|
Paradigm Biocapital Advisors LP
13G/A
|
0% |
2/17/2026
Event 12/31/2025
|
||
| Paradigm BioCapital Advisors LP | 0% | |||
| Paradigm BioCapital Advisors GP LLC | 0% | |||
| Senai Asefaw, M.D. | 0% | |||
| Paradigm BioCapital International Fund Ltd. | 0% | |||
| Period | Filers | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2025 Q4 | 10 | 89.4 k | $5.73M |
| 2025 Q3 | 277 | 71.1 M | $6.69B |
| 2025 Q2 | 205 | 74.8 M | $3.93B |
| 2025 Q1 | 189 | 70.8 M | $2.98B |
| 2024 Q4 | 194 | 70.4 M | $2.96B |
| 2024 Q3 | 193 | 69.0 M | $3.45B |
| 2024 Q2 | 185 | 66.5 M | $3.94B |
| 2024 Q1 | 160 | 51.2 M | $2.31B |
| 2023 Q4 | 135 | 51.2 M | $1.41B |
| 2023 Q3 | 115 | 49.4 M | $1.12B |
| 2023 Q2 | 115 | 41.3 M | $1.09B |
| 2023 Q1 | 106 | 36.5 M | $672M |
| 2022 Q4 | 94 | 36.5 M | $565M |
| 2022 Q3 | 101 | 34.3 M | $687M |
| 2022 Q2 | 94 | 35.0 M | $793M |
| 2022 Q1 | 97 | 33.3 M | $879M |
| 2021 Q4 | 105 | 33.0 M | $1.05B |
| 2021 Q3 | 65 | 22.2 M | $488M |
| 2021 Q2 | 69 | 26.8 M | $564M |
| 2021 Q1 | 60 | 26.7 M | $558M |
| 2020 Q4 | 44 | 21.3 M | $374M |
| 2020 Q3 | 42 | 18.2 M | $218M |
| 2020 Q2 | 44 | 18.6 M | $299M |
| 2020 Q1 | 30 | 18.0 M | $218M |
| 2019 Q4 | 39 | 17.8 M | $251M |
| 2019 Q3 | 27 | 11.9 M | $212M |
| 2019 Q2 | 27 | 11.8 M | $173M |
| 2019 Q1 | 26 | 11.9 M | $175M |
| 2018 Q4 | 27 | 12.1 M | $169M |
| 2018 Q3 | 31 | 12.1 M | $239M |
| 2018 Q2 | 25 | 14.3 M | $326M |
| 2018 Q1 | 20 | 9.80 M | $182M |
| 2017 Q4 | 17 | 5.90 M | $119M |
| 2017 Q3 | 17 | 5.83 M | $116M |
| 2017 Q2 | 17 | 6.31 M | $100M |
| 2017 Q1 | 24 | 6.34 M | $155M |
| 2016 Q4 | 11 | 4.86 M | $103M |
| 2016 Q3 | 12 | 4.74 M | $78.9M |
| 2016 Q2 | 16 | 4.81 M | $38.6M |